<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02803268</url>
  </required_header>
  <id_info>
    <org_study_id>MT-8554-E04</org_study_id>
    <nct_id>NCT02803268</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of MT-8554 in Female Subjects Experiencing Vasomotor Symptoms</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of
      MT-8554 in Female Subjects Experiencing Vasomotor Symptoms
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability as measured by vital signs</measure>
    <time_frame>Up to Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability as measured by number of participants with adverse events</measure>
    <time_frame>Up to Day 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of MT-8554 after dosing</measure>
    <time_frame>Up to Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in core body temperature</measure>
    <time_frame>Up to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Vasomotor Symptoms</measure>
    <time_frame>Up to Day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Vasomotor Symptoms</condition>
  <arm_group>
    <arm_group_label>MT-8554 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who meet eligibility criteria will be administered once daily either low dose of MT-8554 or a matching Placebo from Day 1 to 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MT-8554 middle dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who meet eligibility criteria will be administered once daily either middle dose of MT-8554 or a matching Placebo from Day 1 to 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MT-8554 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who meet eligibility criteria will be administered once daily either high dose of MT-8554 or a matching Placebo from Day 1 to 14.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-8554 low dose</intervention_name>
    <arm_group_label>MT-8554 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-8554 middle dose</intervention_name>
    <arm_group_label>MT-8554 middle dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-8554 high dose</intervention_name>
    <arm_group_label>MT-8554 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>MT-8554 low dose</arm_group_label>
    <arm_group_label>MT-8554 middle dose</arm_group_label>
    <arm_group_label>MT-8554 high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must meet one of the following criteria:Woman aged ≥18 years with
             histologically proven non-metastatic breast cancer (Stages I, II or III) and without
             evidence of disease / Woman aged ≥40 years who are post-menopausal / Woman aged ≥40
             years who are peri-menopausal

          -  Subjects who have ≥7 Vasomotor Symptoms per day on average

          -  A body weight of ≥45 kg

        Exclusion Criteria:

          -  Participation in more than three clinical studies involving administration of an
             unlicensed Investigational Medicinal Product in the previous year, or any study within
             12 weeks

          -  Clinically significant endocrine, thyroid, hepatic, respiratory, gastro-intestinal,
             renal, cardiovascular disease, or history of any significant psychiatric/psychotic
             illness disorder

          -  Clinically relevant abnormal medical history, physical findings or laboratory values
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Investigational center</name>
      <address>
        <city>City name</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2016</study_first_submitted>
  <study_first_submitted_qc>June 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2016</study_first_posted>
  <last_update_submitted>February 9, 2017</last_update_submitted>
  <last_update_submitted_qc>February 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

